157 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Downtrend
Article Searches
Novo Nordisk A/S (NVO) Presents On US Approval Of Ozempic - Slideshow https://seekingalpha.com/article/4130130-novo-nordisk-s-nvo-presents-us-approval-ozempic-slideshow?source=feed_sector_healthcare Dec 06, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes http://www.zacks.com/stock/news/285151/novo-nordisks-semaglutide-gets-fda-approval-for-diabetes?cid=CS-ZC-FT-285151 Dec 06, 2017 - Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.
Sanofi's Toujeo Meets Key Objective in Head-to-Head Study http://www.zacks.com/stock/news/284958/sanofis-toujeo-meets-key-objective-in-head-to-head-study?cid=CS-ZC-FT-284958 Dec 05, 2017 - Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.
Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes http://www.zacks.com/stock/news/284654/pharma-stock-roundup-pfizer-merck-kgaa-drug-fails-in-study-teva-ceo-announces-changes?cid=CS-ZC-FT-284654 Dec 01, 2017 - Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.
5 Biotech and Pharma Stocks with FDA Catalysts this December http://www.zacks.com/stock/news/284530/5-biotech-and-pharma-stocks-with-fda-catalysts-this-december?cid=CS-ZC-FT-284530 Nov 30, 2017 - As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17 http://www.zacks.com/stock/news/284280/2-large-cap-drug-stocks-missing-out-on-industry-rally-in-17?cid=CS-ZC-FT-284280 Nov 28, 2017 - Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.
Novo Nordisk (NVO) Investor Presentation - Slideshow https://seekingalpha.com/article/4127163-novo-nordisk-nvo-investor-presentation-slideshow?source=feed_sector_healthcare Nov 22, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
Novo Nordisk (NVO) Investor Presentation - Slideshow https://seekingalpha.com/article/4127164-novo-nordisk-nvo-investor-presentation-slideshow?source=feed_sector_healthcare Nov 22, 2017 - The following slide deck was published by Novo Nordisk A/S in conjunction with this event.
MannKind CEO Michael Castagna on What's Ahead for the Biotech https://www.fool.com/investing/2017/11/21/mannkind-ceo-michael-castagna-on-whats-ahead-for-t.aspx?source=iedfolrf0000001 Nov 21, 2017 - A conversation with MannKind's CEO about the biotech's future with Afrezza, payers, partners, and pipeline candidates.
An Interview With MannKind CEO Michael Castagna https://www.fool.com/investing/2017/11/19/an-interview-with-mannkind-ceo-michael-castagna.aspx?source=iedfolrf0000001 Nov 19, 2017 - The biotech's CEO talks about how MannKind now has the wind at its back after his first six months at the helm.

Pages: 1...678910111213141516

<<<Page 11>